PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZ0[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

1 . A stable oral pharmaceutical solution comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) and an aqueous pharmaceutical carrier,

wherein Compound 1 is present in the stable oral pharmaceutical solution at a concentration of about 1 mg/mL, and

the stable oral pharmaceutical solution has a pH in a range from about 2 to about 5.

2 - 29 . (canceled)

30 . The stable oral pharmaceutical solution of claim 1 , further comprising a pH adjusting agent, and wherein the aqueous pharmaceutical carrier is water.

31 . The stable oral pharmaceutical solution of claim 30 , wherein the pH adjusting agent is selected from the group consisting of citric acid, phosphoric acid, tartaric acid, succinic acid, formic acid, acetic acid, and combinations thereof.

32 . The stable oral pharmaceutical solution of claim 30 , wherein the pH adjusting agent is citric acid.

33 . The stable oral pharmaceutical solution of claim 30 , further comprising a buffer.

34 . The stable oral pharmaceutical solution of claim 33 , wherein the buffer is selected from the group consisting of citrate, phosphate, tartrate, succinate, formate, acetate, and combinations thereof.

35 . The stable oral pharmaceutical solution of claim 33 , wherein the buffer is sodium citrate.

36 . The stable oral pharmaceutical solution of claim 33 , wherein the pH adjusting agent is citric acid and the buffer is sodium citrate.

37 . The stable oral pharmaceutical solution of claim 33 , further comprising a preservative.

38 . The stable oral pharmaceutical solution of claim 37 , wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, propyl paraben, sodium metabisulfite, potassium sorbate, para-hydroxybenzoic acid, para-hydroxybenzoate, and combinations thereof.

39 . The stable oral pharmaceutical solution of claim 37 , wherein the preservative is sodium benzoate.

40 . The stable oral pharmaceutical solution of claim 37 , further comprising a sweetener.

41 . The stable oral pharmaceutical solution of claim 40 , wherein the sweetener is selected from the group consisting of sucralose, acesulfame potassium, sodium saccharin, neotame, sucrose, maltitol, xylitol, and combinations thereof.

42 . The stable oral pharmaceutical solution of claim 40 , wherein the sweetener is sucralose.

43 . The stable oral pharmaceutical solution of claim 40 , comprising:

Compound 1;

sodium benzoate;

sucralose;

citric acid;

sodium citrate; and

water.

44 . The stable oral pharmaceutical solution of claim 43 , comprising:

1.0 mg/mL of Compound 1;

0.3 mg/mL of sodium benzoate;

9.0 mg/mL of sucralose;

2.13 mg/mL of citric acid;

0.45 mg/mL of sodium citrate; and

water.

45 . A process for preparing the stable oral pharmaceutical solution of claim 1 , the process comprising combining a crystalline form of Compound 1 and the aqueous pharmaceutical carrier.

46 . A process for preparing the stable oral pharmaceutical solution of claim 1 , the process comprising combining amorphous freebase Compound 1 and the aqueous pharmaceutical carrier.

47 . A process for preparing the stable oral pharmaceutical solution of claim 33 , the process comprising combining a crystalline form of Compound 1 and the aqueous pharmaceutical carrier.

48 . A process for preparing the stable oral pharmaceutical solution of claim 33 , the process comprising combining amorphous freebase Compound 1, the pH adjusting agent, the buffer, and the water.

49 . A stable oral pharmaceutical solution comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) and an aqueous pharmaceutical carrier;

wherein Compound 1 is present in the stable oral pharmaceutical solution at a concentration of about 1 mg/ml;

wherein the stable oral pharmaceutical solution has a pH in a range from about 2 to about 5; and

wherein the stable oral pharmaceutical solution is produced by a process comprising combining Compound 1 and the aqueous pharmaceutical carrier.

50 . The stable oral pharmaceutical solution of claim 49 , produced by a process comprising combining a crystalline form of Compound 1 and the aqueous pharmaceutical carrier.

51 . The stable oral pharmaceutical solution of claim 49 , produced by a process comprising combining amorphous freebase Compound 1 and the aqueous pharmaceutical carrier.

52 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent, produced by a process comprising combining a crystalline form of Compound 1, the pH adjusting agent, and the aqueous pharmaceutical carrier.

53 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent, produced by a process comprising combining amorphous freebase Compound 1, the pH adjusting agent, and the aqueous pharmaceutical carrier.

54 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent and a buffer, produced by a process comprising combining a crystalline form of Compound 1, the pH adjusting agent, the buffer, and the aqueous pharmaceutical carrier.

55 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent and a buffer, produced by a process comprising combining amorphous freebase Compound 1, the pH adjusting agent, the buffer, and the aqueous pharmaceutical carrier.

56 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent, a buffer, and a preservative, produced by a process comprising combining a crystalline form of Compound 1, the pH adjusting agent, the buffer, the preservative, and the aqueous pharmaceutical carrier.

57 . The stable oral pharmaceutical solution of claim 49 , further comprising a pH adjusting agent, a buffer, and a preservative, produced by a process comprising combining amorphous freebase Compound 1, the pH adjusting agent, the buffer, the preservative, and the aqueous pharmaceutical carrier.